(Insulin glargine + insulin lispro) LA is under clinical development by Adocia and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect (Insulin glargine + insulin lispro) LA’s likelihood of approval (LoA) and phase transition for Type 2 Diabetes took place on 14 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Insulin glargine + insulin lispro) LA Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

(Insulin glargine + insulin lispro) LA overview

BioChaperone combo, is a pre-mixed liquid formulation containing both long-acting insulin analog glargine and fast-acting insulin analog lispro is under development for the treatment of type 1 diabetes and type 2 diabetes. The drug candidate is administered subcutaneously. The drug candidate acts by targeting insulin receptor (IR). The drug candidate is developed based on BioChaperone technology.

Adocia overview

Adocia is a biotechnology company, which carries out the development of therapeutic proteins and peptides. The company’s clinical pipeline product offerings include Biochaperone Lispro insulin, Biochaperone Combo for type-2 diabetes, M1Pram for type-1 diabetes, Biochaperone Glucagon for hyperglycemia, Biochaperone GLA GLP-1 basal insulin and Biochaperone Glucagon GLP-1 for Obesity. Its BioChaperone is a proprietary technology platform developed from polymers, oligomers and small organic compounds, protects proteins from enzymatic degradation and enhances performance. The company also provides preclinical stage cell therapy concentrating on the development of a hydrogel scaffold for people diagnosed with type 1 diabetes. Adocia is headquartered in Lyon, Auvergne-Rhone-Alpes, France.

Quick View (Insulin glargine + insulin lispro) LA LOA Data

Report Segments
  • Innovator
Drug Name
  • (Insulin glargine + insulin lispro) LA
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.